A pharmaceutical composition containing an antibody recognizing the cdw52 antigen
CA 2060384 C · Owner: British Technology Group Limited · Inventors: Hale, Geoffrey; Waldmann, Herman
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a method of treatment of a human or animal subject suffering from T-cell mediated inflammation of the joints, such as rheumatoid arthritis which comprises administering to said subject an effective amount of an antibody recognising the CDw52 antigen. Preferably the antibody is CAMPATH-1H administered in an amount of 1 to about 100mg per day for a period between 1 and 30 days.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 30, 1992 and granted June 12, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 30, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 30, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.